Tebentafusp 100micrograms/0.5ml solution for infusion vials
NHS hospitals in England used £205,194,450 of indicative cost of Tebentafusp 100micrograms/0.5ml solution for infusion vials in the 12 months to July 2026, about 0.8% of all hospital medicines spend. That is up 186.1% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Tebentafusp 100micrograms/0.5ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Tebentafusp 100micrograms/0.5ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Christie Nhs Foundation Trust | £175,154,859 |
| The Clatterbridge Cancer Centre Nhs Ft | £8,768,838 |
| The Royal Marsden Nhs Foundation Trust | £4,430,337 |
| Univ Hpl B/Ham Nhs Foundation Trust | £2,730,780 |
| Hull And East Yorkshire Hpls Nhs Trust | £2,316,106 |
| Southend Univ Hosp Nhs Foundation Trust | £1,456,416 |
| Cambridge Univ Hosp Nhs Foundation Trust | £1,406,048 |
| Norfolk & Norwich University Hpl Nhs Trt | £1,294,592 |
| Western Sussex Hospitals Nhs Found Trust | £1,284,478 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £1,193,452 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.